Show source-provided references
1. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, et al. Cancer statistics, 2020: Report from National Cancer Registry Programme, India. JCO Glob Oncol. 2020;6:1063–75. 10.1200/GO.20.00122.
10.1200/GO.20.00122 ↗2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: Cancer J Clin. 2023;73(1):17–48. 10.3322/caac.21763.
10.3322/caac.21763 ↗3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229–63. 10.3322/caac.21834.
10.3322/caac.21834 ↗4. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, et al. Estimating the global cancer incidence and mortality in 2018: Globocan sources and methods. Int J Cancer. 2019;144(8):1941–53. 10.1002/ijc.31937.
10.1002/ijc.31937 ↗5. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30. 10.1002/cncr.33587.
10.1002/cncr.33587 ↗6. Chhikara BS, Parang K. Global cancer statistics 2022: The trends projection analysis. Chem Biol Lett. 2023;10(1):451.
7. Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: From tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84. 10.1101/gad.314617.118.
10.1101/gad.314617.118 ↗8. Pulumati A, Pulumati A, Dwarakanath BS, Verma A, Papineni RV. Technological advancements in cancer diagnostics: Improvements and limitations. Cancer Rep. 2023;6(2):e1764. 10.1002/cnr2.1764.
10.1002/cnr2.1764 ↗9. Hajjafari A, Sadr S, Rahdar A, Bayat M, Lotfalizadeh N, Dianaty S, et al. Exploring the integration of nanotechnology in the development and application of biosensors for enhanced detection and monitoring of colorectal cancer. Inorg Chem Commun. 2024;8:112409. 10.1016/j.inoche.2024.112409.
10.1016/j.inoche.2024.112409 ↗10. Misra R, Acharya S, Sahoo SK. Cancer nanotechnology: Application of nanotechnology in cancer therapy. Drug Discov Today. 2010;15(19–20):842–50. 10.1016/j.drudis.2010.08.006.
10.1016/j.drudis.2010.08.006 ↗11. Hartman KB, Wilson LJ, Rosenblum MG. Detecting and treating cancer with nanotechnology. Mol Diagn Ther. 2008;12:1–14. 10.1007/BF03256264.
10.1007/BF03256264 ↗12. Goforth R, Salem AK, Zhu X, Miles S, Zhang X-Q, Lee JH, et al. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma. Cancer Immunol Immunother. 2009;58:517–30. 10.1007/s00262-008-0574-6.
10.1007/s00262-008-0574-6 ↗13. Cai X, Zhang L, Wei W. Regulatory B cells in inflammatory diseases and tumor. Int Immunopharmacol. 2019;67:281–6. 10.1016/j.intimp.2018.12.007.
10.1016/j.intimp.2018.12.007 ↗14. Rosales-Mendoza S, González-Ortega O, Rosales-Mendoza S, González-Ortega O. Nanovaccines and the history of vaccinology. Nanovaccines: An innovative technology to fight human and animal diseases. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 1–14. 10.1007/978-3-030-31668-6.
10.1007/978-3-030-31668-6_1 ↗15. Sekhon BS, Saluja V. Nanovaccines-an overview. Int J Pharm Front Res. 2011;1(1):101–9.
10.2147/BS.S16120 ↗16. Wagner DA, Kelly SM, Petersen AC, Peroutka-Bigus N, Darling RJ, Bellaire BH, et al. Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague. Acta Biomater. 2019;100:326–37. 10.1016/j.actbio.2019.10.016.
10.1016/j.actbio.2019.10.016 ↗17. Gurunathan S, Thangaraj P, Wang L, Cao Q, Kim J-H. Nanovaccines: An effective therapeutic approach for cancer therapy. Biomed Pharmacother. 2024;170:115992. 10.1016/j.biopha.2023.115992.
10.1016/j.biopha.2023.115992 ↗18. Nierkens S, Tel J, Janssen E, Adema GJ. Antigen cross-presentation by dendritic cell subsets: One general or all sergeants? Trends Immunol. 2013;34(8):361–70. 10.1016/j.it.2013.02.007.
10.1016/j.it.2013.02.007 ↗19. Embgenbroich M, Burgdorf S. Current concepts of antigen cross-presentation. Front Immunol. 2018;9:1643. 10.3389/fimmu.2018.01643.
10.3389/fimmu.2018.01643 ↗20. Cai T, Liu H, Zhang S, Hu J, Zhang L. Delivery of nanovaccine towards lymphoid organs: Recent strategies in enhancing cancer immunotherapy. J Nanobiotechnol. 2021;19:1–23. 10.1186/s12951-021-01146-2.
10.1186/s12951-021-01146-2 ↗21. El-Sayed N, Korotchenko E, Scheiblhofer S, Weiss R, Schneider M. Functionalized multifunctional nanovaccine for targeting dendritic cells and modulation of immune response. Int J Pharm. 2021;593:120123. 10.1016/j.ijpharm.2020.120123.
10.1016/j.ijpharm.2020.120123 ↗22. Aku AM, Patil A. Understanding cancer etiology: A review of the evidence-based ayurvedic framework of cancer etiologies. Int Q J Res Ayurveda. 2022;43(1):1–7. 10.4103/ayu.ayu_318_21.
10.4103/ayu.ayu_318_21 ↗23. Hill BT. Etiology of cancer. Clinical ophthalmic oncology: Basic principles. Cham, Switzerland: Springer Nature Switzerland AG; 2019. p. 11–7. 10.1007/978-3-030-04489-3_2.
10.1007/978-3-030-04489-3_2 ↗24. Shemesh CS, Hsu JC, Hosseini I, Shen B-Q, Rotte A, Twomey P, et al. Personalized cancer vaccines: Clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555–70. 10.1016/j.ymthe.2020.09.038.
10.1016/j.ymthe.2020.09.038 ↗25. Butterfield LH. Cancer vaccines. BMJ. 2015;350:1–14. 10.1136/bmj.h988.
10.1136/bmj.h988 ↗26. Saxena M, van der Burg SH, Melief CJ, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21(6):360–78. 10.1038/s41568-021-00346-0.
10.1038/s41568-021-00346-0 ↗27. DeMaria PJ, Bilusic M. Cancer vaccines. Hematol/Oncol Clin. 2019;33(2):199–214. 10.1016/j.hoc.2018.12.001.
10.1016/j.hoc.2018.12.001 ↗28. Thomas S, Prendergast GC. Cancer vaccines: A brief overview. Vaccine design: Methods and protocols volume 1: Vaccines for human diseases. New York, NY, USA: Springer Science Business Media; 2016. p. 755–61. 10.1007/978-1-4939-3387-7_43.
10.1007/978-1-4939-3387-7_43 ↗29. Isaguliants MG, Ivanov AV, Buonaguro FM. Chronic viral infections and cancer, openings for therapies and vaccines. Switzerland: MDPI; 2024. p. 818.
10.3390/cancers16040818 ↗30. Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Phys J. 2016;62(5):399–402.
31. Monie A, Hung C-F, Roden R, Wu TC. Cervarix™: A vaccine for the prevention of Hpv 16, 18-associated cervical cancer. Biol: Targets Ther. 2008;2(1):107–13.
10.2147/BTT.S1877 ↗32. Elbahrawy A, Atalla H, Alboraie M, Alwassief A, Madian A, El Fayoumie M, et al. Recent advances in protective vaccines against hepatitis viruses: A narrative review. Viruses. 2023;15(1):214. 10.3390/v15010214.
10.3390/v15010214 ↗33. Institute CR. Cancer vaccines. New York, NY, USA: Cancer Research Institute; 2025.
34. Islami F, Kamangar F. Helicobacter Pylori and esophageal cancer risk: A meta-analysis. Cancer Prev Res. 2008;1(5):329–38. 10.1158/1940-6207.CAPR-08-0109.
10.1158/1940-6207.CAPR-08-0109 ↗35. Nie S, Chen T, Yang X, Huai P, Lu M. Association of Helicobacter pylori infection with esophageal adenocarcinoma and squamous cell carcinoma: A meta-analysis. Dis Esophagus. 2014;27(7):645–53. 10.1111/dote.12194.
10.1111/dote.12194 ↗36. Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. Helicovax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine. 2011;29(11):2085–91. 10.1016/j.vaccine.2010.12.130.
10.1016/j.vaccine.2010.12.130 ↗37. Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2019;37(50):7295–9. 10.1016/j.vaccine.2018.01.001.
10.1016/j.vaccine.2018.01.001 ↗38. Anassi E, Ndefo UA. Sipuleucel-T (provenge) injection: The first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharm Ther. 2011;36(4):197.
39. Okafor CN, Rewane A, Momodu II. Bacillus calmette guerin. Europe PMC. United Kingdom: StatPearls Publishing; 2019.
40. Nakajima EC, Vellanki PJ, Larkins E, Chatterjee S, Mishra-Kalyani PS, Bi Y, et al. FDA approval summary: Nivolumab in combination with ipilimumab for the treatment of unresectable malignant pleural mesothelioma. Clin Cancer Res. 2022;28(3):446–51. 10.1158/1078-0432.CCR-21-1466.
10.1158/1078-0432.CCR-21-1466 ↗41. Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: The checkmate 016 study. J Clin Oncol. 2017;35(34):3851–8. 10.1200/jco.2016.72.1985.
10.1200/JCO.2016.72.1985 ↗42. Stewart J Yervoy FDA approval history. Auckland, New Zealand: Drugs.com; 2025.
43. Drug UFa. FDA grants accelerated approval to ipilimumab for Msi-H or Dmmr metastatic colorectal cancer. Silver Spring, Maryland, United States: U.S. Food and Drug Administration (FDA); 2023.
45. FDA. Chemotherapy for her2-negative gastric or gastroesophageal junction adenocarcinoma. Silver Spring, Maryland, USA: U.S. Food and Drug Administration (FDA); 2023.
46. Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annu Rev Pathol: Mech Dis. 2021;16(1):223–49. 10.1146/annurev-pathol-042020-042741.
10.1146/annurev-pathol-042020-042741 ↗47. Keytruda. Treats 16 types of cancer. New Jersey, USA: Merck Sharp & Dohme Corp.; 2024.
48. FDA. Fda D.I.S.C.O. Burst edition: FDA approval of Fruzaqla (Fruquintinib) for adult patients with metastatic colorectal cancer. Silver Spring, Maryland, United States: U.S. Food and Drug Administration (FDA); 2023.
49. Institute NC. Fruquintinib. Bethesda, Maryland, United States: National Cancer Institute (NCI); 2023. https://www.cancer.gov/about-cancer/treatment/drugs/fruquintinib.
50. Cheever MA, Higano CS. Provenge (Sipuleucel-T) in prostate cancer: The first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011;17(11):3520–6. 10.1158/1078-0432.CCR-10-3126.
10.1158/1078-0432.CCR-10-3126 ↗51. Signorelli C, Odone A, Ciorba V, Cella P, Audisio R, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: A systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962–82.
10.1017/S0950268817000747 ↗52. Zhu F, Li J, Hu Y, Zhang X, Yang X, Zhao H, et al. Immunogenicity and safety of the Hpv-16/18 As04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: Results from 2 randomized controlled trials. Hum Vaccines Immunother. 2014;10(7):1795–806. 10.4161/hv.28702.
10.4161/hv.28702 ↗53. Guallar-Garrido S, Julián E. Bacillus Calmette-Guérin (BCG) therapy for bladder cancer: An update. Immunotargets Ther. 2020;9:1–11. 10.2147/ITT.S202006.
10.2147/ITT.S202006 ↗54. Hodi FS, O’day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–23. 10.1056/NEJMoa1003466.
55. Burns MC, O’donnell A, Puzanov I. Pembrolizumab for the treatment of advanced melanoma. Expert Opin Orphan Drugs. 2016;4(8):867–73. 10.1080/21678707.2016.1191348.
10.1080/21678707.2016.1191348 ↗56. Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, et al. FDA approval summary: Repotrectinib for locally advanced or metastatic Ros1-positive non–small cell lung cancer. Clin Cancer Res. 2024;30(16):3364–70. 10.1158/1078-0432.CCR-24-0949.
10.1158/1078-0432.CCR-24-0949 ↗57. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (Fresco-2): An international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41–53. 10.1016/S0140-6736(23)00772-9.
10.1016/S0140-6736(23)00772-9 ↗58. Hou Y, Li Y, Zhang Y, Zhang J, Wu D. Current status and future directions of nanovaccine for cancer: A bibliometric analysis during 2004–2023. Front Immunol. 2024;15:1423212. 10.3389/fimmu.2024.1423212.
10.3389/fimmu.2024.1423212 ↗59. Liu M, Xie D, Hu D, Zhang R, Wang Y, Tang L, et al. In situ cocktail nanovaccine for cancer immunotherapy. Adv Sci. 2023;10(31):2207697. 10.1002/advs.202207697.
10.1002/advs.202207697 ↗60. Carson CS, Becker KW, Garland KM, Pagendarm HM, Stone PT, Arora K, et al. A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyic RNA. J Control Release. 2022;345:354–70. 10.1016/j.jconrel.2022.03.020.
10.1016/j.jconrel.2022.03.020 ↗61. Ishikawa H, Barber GN. Sting is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature. 2008;455(7213):674–8. 10.1038/nature07317.
10.1038/nature07317 ↗62. Gallego-Marin C, Schrum JE, Andrade WA, Shaffer SA, Giraldo LF, Lasso AM, et al. Cyclic Gmp–Amp synthase is the cytosolic sensor of Plasmodium falciparum genomic DNA and activates type I Ifn in malaria. J Immunol. 2018;200(2):768–74. 10.4049/jimmunol.1701048.
10.4049/jimmunol.1701048 ↗63. Vatner RE, Janssen EM. Sting, DCs and the link between innate and adaptive tumor immunity. Mol Immunol. 2019;110:13–23. 10.1016/j.molimm.2017.12.001.
10.1016/j.molimm.2017.12.001 ↗64. Li S, Mirlekar B, Johnson BM, Brickey WJ, Wrobel JA, Yang N, et al. Sting-induced regulatory B cells compromise Nk function in cancer immunity. Nature. 2022;610(7931):373–80. 10.1038/s41586-022-05254-3.
10.1038/s41586-022-05254-3 ↗65. Zhang B, Zhang J, Li Y, Li N, Wang Y, Jang R, et al. In situ sting‐activating nanovaccination with tigit blockade for enhanced immunotherapy of anti‐Pd‐1‐resistant tumors. Adv Mater. 2023;35(24):2300171. 10.1002/adma.202300171.
10.1002/adma.202300171 ↗66. Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: Sting agonists in cancer therapy. Oncoimmunol. 2020;9(1):1777624. 10.1080/2162402X.2020.1777624.
10.1080/2162402X.2020.1777624 ↗67. Chacko RT, Ventura J, Zhuang J, Thayumanavan S. Polymer nanogels: A versatile nanoscopic drug delivery platform. Adv Drug Deliv Rev. 2012;64(9):836–51. 10.1016/j.addr.2012.02.002.
10.1016/j.addr.2012.02.002 ↗68. Neamtu I, Rusu AG, Diaconu A, Nita LE, Chiriac AP. Basic concepts and recent advances in nanogels as carriers for medical applications. Drug Deliv. 2017;24(1):539–57. 10.1080/10717544.2016.1276232.
10.1080/10717544.2016.1276232 ↗69. Paul SD, Sharma H, Jeswani G, Jha AK. Novel gels: Implications for drug delivery. Nanostructures for drug delivery. Amsterdam, The Netherlands: Elsevier; 2017. p. 379–412.
10.1016/B978-0-323-46143-6.00012-9 ↗70. Attama AA, Nnamani PO, Onokala OB, Ugwu AA, Onugwu AL. Nanogels as target drug delivery systems in cancer therapy: A review of the last decade. Front Pharmacol. 2022;13:874510. 10.3389/fphar.2022.874510.
10.3389/fphar.2022.874510 ↗71. Tornesello AL, Tagliamonte M, Tornesello ML, Buonaguro FM, Buonaguro L. Nanoparticles to improve the efficacy of peptide-based cancer vaccines. Cancers. 2020;12(4):1049. 10.3390/cancers12041049.
10.3390/cancers12041049 ↗72. Lv Q, He C, Quan F, Yu S, Chen X. Dox/Il-2/Ifn-Γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment. Bioact Mater. 2018;3(1):118–28. 10.1016/j.bioactmat.2017.08.003.
10.1016/j.bioactmat.2017.08.003 ↗73. Tang L, Zheng Y, Melo MB, Mabardi L, Castaño AP, Xie Y-Q, et al. Enhancing T cell therapy through Tcr-signaling-responsive nanoparticle drug delivery. Nat Biotechnol. 2018;36(8):707–16. 10.1038/nbt.4181.
10.1038/nbt.4181 ↗74. Liu K, Zheng D, Zhao J, Tao Y, Wang Y, He J, et al. Ph-sensitive nanogels based on the electrostatic self-assembly of radionuclide 131 I labeled albumin and carboxymethyl cellulose for synergistic combined chemo-radioisotope therapy of cancer. J Mater Chem B. 2018;6(29):4738–46. 10.1039/C8TB01295D.
10.1039/C8TB01295D ↗75. Jiang L, Zhou Q, Mu K, Xie H, Zhu Y, Zhu W, et al. Ph/temperature sensitive magnetic nanogels conjugated with Cy5. 5-labled lactoferrin for Mr and fluorescence imaging of glioma in rats. Biomaterials. 2013;34(30):7418–28. 10.1016/j.biomaterials.2013.05.078.
10.1016/j.biomaterials.2013.05.078 ↗76. Manimaran V, Nivetha R, Tamilanban T, Narayanan J, Vetriselvan S, Fuloria NK, et al. Nanogels as novel drug nanocarriers for CNS drug delivery. Front Mol Biosci. 2023;10:1232109. 10.3389/fmolb.2023.1232109.
10.3389/fmolb.2023.1232109 ↗77. Zhao X, Han Y, Sun Y, Feng W, Liu J, Li D, et al. Combining photothermal ablation-based vaccine with immune checkpoint blockade for synergistic osteosarcoma immunotherapy. Mater Des. 2021;198:109311. 10.1016/j.matdes.2020.109311.
10.1016/j.matdes.2020.109311 ↗78. Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17(11):657–74. 10.1038/s41571-020-0410-2.
10.1038/s41571-020-0410-2 ↗79. Shen S, Gao Y, Ouyang Z, Jia B, Shen M, Shi X. Photothermal-triggered dendrimer nanovaccines boost systemic antitumor immunity. J Control Release. 2023;355:171–83. 10.1016/j.jconrel.2023.01.076.
10.1016/j.jconrel.2023.01.076 ↗80. Li T, Chen G, Xiao Z, Li B, Zhong H, Lin M, et al. Surgical tumor-derived photothermal nanovaccine for personalized cancer therapy and prevention. Nano Lett. 2022;22(7):3095–103. 10.1021/acs.nanolett.2c00500.
10.1021/acs.nanolett.2c00500 ↗81. Sun R, Liu M, Lu J, Chu B, Yang Y, Song B, et al. Bacteria loaded with glucose polymer and photosensitive Icg silicon-nanoparticles for glioblastoma photothermal immunotherapy. Nat Commun. 2022;13(1):5127. 10.1038/s41467-022-32837-5.
10.1038/s41467-022-32837-5 ↗82. Li J, Huang D, Cheng R, Figueiredo P, Fontana F, Correia A, et al. Multifunctional biomimetic nanovaccines based on photothermal and weak‐immunostimulatory nanoparticulate cores for the immunotherapy of solid tumors. Adv Mater. 2022;34(9):2108012. 10.1002/adma.202108012.
10.1002/adma.202270074 ↗83. He Q, Gao H, Tan D, Zhang H, Wang J-Z. mRNA cancer vaccines: Advances, trends and challenges. Acta Pharm Sin B. 2022;12(7):2969–89. 10.1016/j.apsb.2022.03.011.
10.1016/j.apsb.2022.03.011 ↗84. Fujita Y, Taguchi H. Nanoparticle-based peptide vaccines. Micro and nanotechnology in vaccine development. Oxford, United Kingdom: Elsevier; 2017. p. 149–70.
10.1016/B978-0-323-39981-4.00008-7 ↗85. Wang J, Mamuti M, Wang H. Therapeutic vaccines for cancer immunotherapy. ACS Biomater Sci Eng. 2020;6(11):6036–52. 10.1021/acsbiomaterials.0c01201.
10.1021/acsbiomaterials.0c01201 ↗86. Huang T, Peng L, Han Y, Wang D, He X, Wang J, et al. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol. 2022;13:922301. 10.3389/fimmu.2022.922301.
10.3389/fimmu.2022.922301 ↗87. Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, et al. Virus-like particle (VLP) vaccines for cancer immunotherapy. Int J Mol Sci. 2023;24(16):12963. 10.3390/ijms241612963.
10.3390/ijms241612963 ↗88. Han J, Zhao D, Li D, Wang X, Jin Z, Zhao K. Polymer-based nanomaterials and applications for vaccines and drugs. Polymers. 2018;10(1):31. 10.3390/polym10010031.
10.3390/polym10010031 ↗89. Liu C, Xia C, Xia C. Biology and function of exosomes in tumor immunotherapy. Biomed Pharmacother. 2023;169:115853. 10.1016/j.biopha.2023.115853.
10.1016/j.biopha.2023.115853 ↗90. Ferrando RM, Lay L, Polito L. Gold nanoparticle-based platforms for vaccine development. Drug Discov Today: Technol. 2020;38:57–67. 10.1016/j.ddtec.2021.02.001.
10.1016/j.ddtec.2021.02.001 ↗91. He J-S, Liu S-J, Zhang Y-R, Chu X-D, Lin Z-B, Zhao Z, et al. The application of and strategy for gold nanoparticles in cancer immunotherapy. Front Pharmacol. 2021;12:687399. 10.3389/fphar.2021.687399.
10.3389/fphar.2021.687399 ↗92. Ning L, Zhu B, Gao T. Gold nanoparticles: Promising agent to improve the diagnosis and therapy of cancer. Curr Drug Metab. 2017;18(11):1055–67. 10.2174/1389200218666170925122513.
10.2174/1389200218666170925122513 ↗93. Thakur N, Thakur S, Chatterjee S, Das J, Sil PC. Nanoparticles as smart carriers for enhanced cancer immunotherapy. Front Chem. 2020;8:597806. 10.3389/fchem.2020.597806.
10.3389/fchem.2020.597806 ↗94. Liu J, Miao L, Sui J, Hao Y, Huang G. Nanoparticle cancer vaccines: Design considerations and recent advances. Asian J Pharm Sci. 2020;15(5):576–90. 10.1016/j.ajps.2019.10.006.
10.1016/j.ajps.2019.10.006 ↗95. Sousa AR, Oliveira MJ, Sarmento B. Impact of CEA-targeting nanoparticles for drug delivery in colorectal cancer. J Pharmacol Exp Ther. 2019;370(3):657–70. 10.1124/jpet.118.254441.
10.1124/jpet.118.254441 ↗96. Zhong J, Qiao R, Yuan W-E. Protein-based nanocarriers for delivery of nutraceutical, diagnostic and therapeutic agents. Lausanne, Switzerland: Frontiers Media SA; 2022. p. 991474.
10.3389/fphar.2022.991474 ↗97. Wang B, Xu X, Li B, Wei Z, Lu S, Li J, et al. Protein-based nanocarriers for efficient etoposide delivery and cancer therapy. Nano Res. 2023;16(8):11216–20. 10.1007/s12274-023-5841-5.
10.1007/s12274-023-5841-5 ↗98. Laurent S, Burtea C, Thirifays C, Rezaee F, Mahmoudi M. Significance of cell “observer” and protein source in nanobiosciences. J Colloid Interface Sci. 2013;392:431–45. 10.1016/j.jcis.2012.10.005.
10.1016/j.jcis.2012.10.005 ↗99. Kianfar E. Protein nanoparticles in drug delivery: Animal protein, plant proteins and protein cages, albumin nanoparticles. J Nanobiotechnol. 2021;19(1):159. 10.1186/s12951-021-00896-3.
10.1186/s12951-021-00896-3 ↗100. Dileo J, Banerjee R, Whitmore M, Nayak JV, Falo LD, Huang L. Lipid–protamine–DNA-mediated antigen delivery to antigen-presenting cells results in enhanced anti-tumor immune responses. Mol Ther. 2003;7(5):640–8. 10.1016/S1525-0016(03)00064-9.
10.1016/S1525-0016(03)00064-9 ↗